The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

Video content above is prompted by the following: Aqua Ablation Therapy Benefits Efficacy: Aqua ablation demonstrates noninferior, equal, or superior results compared with TURP (gold standard).

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study. “If you look at the data, it's phenomenal data. It's the highest [complete response] CR rate ...

"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD. Data presented at the 2025 American Urological ...

In an interview with Urology Times®, John L. Gore, MD, MS, FACS, shares the background and key findings from the study, “Radical Cystectomy Versus Bladder-Sparing Therapy For Recurrent High-Grade ...

Higher levels of drinking water contaminants are associated with increased kidney stone burden and recurrence, independent of socioeconomic factors. The study analyzed over 1100 California residents, ...

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s ...

Sasanlimab plus BCG significantly improved EFS compared to BCG alone in high-risk NMIBC patients, with a 32% lower risk of EFS events. The study involved 1055 BCG-naïve patients, focusing on EFS, ...

Social media platforms are major sources of prostate cancer misinformation, affecting patient education and care provider relationships. Misinformation is often spread by unlicensed individuals posing ...

In an interview with Urology Times®, Jason M. Hafron, MD, CMO, discusses his talk, “Barriers in Recruiting and Running Effective Clinical Trials in Independent Practices,” which was presented at the ...

The Break Wave System offers a noninvasive, anesthesia-free option for kidney stone treatment using low-pressure ultrasound waves. The SOUND trial enrolled 64 patients to assess the system's safety ...

TARA-002 demonstrated a 100% high-grade complete response in BCG-unresponsive patients at 6 months, with a 76% CR in BCG-naïve patients. The agent acts as a broad-spectrum immune potentiator, ...